Healthy Returns: What's next for Novo Nordisk's next-generation obesity drug CagriSema after trial miss

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026.A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Novo Nordisk isn't catching a break this year. Shares of the Danish drugmaker plummeted on Monday after it released data showing that its next-generation obesity drug failed to match the we ...